Navigation Links
Frost & Sullivan: Key Therapeutic Areas to Remain Strongest Drivers of CRO Revenue Growth in the United States
Date:9/21/2009

MOUNTAIN VIEW, Calif., Sept. 21 /PRNewswire/ -- The economic downturn and reduction in funding for early stage projects is likely to result in a decline in growth rate across major therapeutic segments in the short-to-medium term. However, due to this lack of funding, it is unlikely that pharmaceutical and biotechnology companies will invest in in-house capabilities to conduct clinical trials. This is set to benefit contract research organizations (CROs) in obtaining continued business from this segment. Despite possible defaults on payments for projects from a few companies that could affect CROs in the short term, oncology, central nervous system, and cardiovascular are expected to remain as key therapeutic areas.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan (http://www.pharma.frost.com), U.S. CRO Markets - Key Therapeutic Areas, finds that the market earned revenues of over $10.91 billion in 2009 and estimates this to reach $22.87 billion in 2015. The markets covered in this research include preclinical to phase IV CRO services for pharmaceuticals and biotechnology.

If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an e-mail to Johanna Haynes at johanna.haynes@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country.

"The most interesting aspect of CRO market growth has been that of new sponsors - increasingly biotechnology companies and specialty pharmaceutical companies - with a demand for full services spanning the pre-clinical to the post-commercialization stage," says Frost & Sullivan Senior Industry Analyst Barath Shankar Subramanian. "This could be attributed to the limited development infrastructure with sponsors, leading to CROs being viewed as strategic partners."

Earlier, the trend in the market used to be start-up pharmaceutical and biotechnology companies out-licensing their product beyond phase I/II or getting acquired, which posed a great deal of uncertainty over the future of the project. Nowadays, companies are increasingly retaining products within their pipeline and continuing to take them closer to the market through CROs, thereby enhancing the value of the products and the company.

Despite optimistic forecasts for the market, a growing divide between patient access and studies is threatening productivity. Trials continue to become increasingly complex and global, resulting in intense competition for access to patients, new investigators, and innovative studies.

The divide between patient access and studies has been rising consistently over the past decade and could affect future studies. For studies that depend heavily on the emerging markets, this could have a negative impact on productivity by lengthening trial times. In addition, an underlying churn in existing investigators is further widening this divide.

"CROs and sponsors are looking at innovative ways to increase access to patients by partnering with patient recruitment firms," concludes Subramanian. "Service providers are also outsourcing large-scale global trials through the expanded reach of CRO partners, enabling access to an extensive patient pool."

U.S. CRO Markets - Key Therapeutic Areas is part of the Pharmaceuticals & Biotechnology Growth Partnership Services program, which also includes research in the following markets: U.S. Contract Research Organizations Markets; Global CRO Spending Trends; Global Biopharmaceutical Contract Manufacturing Market; and Strategic Analysis of Opportunities in the CRO Market - Phase 0. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

U.S. CRO Markets - Key Therapeutic Areas

N579

    Contact:

    Johanna Haynes
    Corporate Communications - North America
    P: 210.247.3870
    F: 210.348.1003
    E: johanna.haynes@frost.com

http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Supernanny Jo Frost Joins the Partnership for a Drug-Free America in Supporting Time To Talk(TM)
2. Masimo Corporation Receives a Frost & Sullivan 2007 Industry Best Practices Award for Pulse Oximetry Leadership
3. Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award
4. Novadaqs SPY Imaging System named Product of the Year by Frost and Sullivan
5. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
6. Kelloggs Frosted Flakes Gold(TM) Helps Moms Get the Gold
7. MedApps Receives Prestigious Frost & Sullivan Award
8. Nancy Frost Joins Lawson-Hawks as Employee Benefits Vice President
9. Accurays CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan
10. Help Your Kids Earn an A for Attentiveness with a Bowl of Frosted Mini- Wheats(R) Cereal for Breakfast
11. Therapy Could Save Limbs After Frostbite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2017)... ... May 28, 2017 , ... Viewers likely know Rob Lowe from such ... also noted for his work on NBC’s The West Wing and Parks and Recreation. ... new series “Informed,” which puts the spotlight on important modern-day issues that face today’s ...
(Date:5/27/2017)... ... May 27, 2017 , ... From May 21-23, hearing healthcare ... three-day event was held at the Marriott Syracuse Downtown Hotel in Syracuse, New York. ... and network of independent hearing healthcare providers to help them stay ahead in the ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... gather at Boston CEO 2017 on May 30th and 31st at The Four ... forum for leading executives in the life sciences, offering exclusive access to key ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of community health data ... are located in the Midwest. With the average cost of healthcare rising and the ... with both the quality and affordability of where they live. An annual 2017 report ...
(Date:5/26/2017)... ... May 26, 2017 , ... After raising nearly $30,000 on ... will continue to be available at a discounted crowdfunding price on Indiegogo . ... they are, I also wanted to bring a fidget toy to the market that ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... announced it has earned a spot on Forbes, ... Company was ranked among 500 U.S. employers as well ... Equipment and Services. The annual Forbes ... independent survey of over 30,000 employees across 25 industries. ...
(Date:5/9/2017)... 2017  Semler Scientific, Inc. (OTCQB: SMLR), an ... improve the clinical effectiveness and efficiency of healthcare ... quarter ended March 31, 2017. ... to identify when preventive care options are appropriate, ... heart attacks or strokes occur," said Doug ...
(Date:5/6/2017)... , May 5, 2017   Provista , a ... more than 200,000 customers, today announced Jim Cunniff ... wealth of executive and business experience to Provista, including most ... pharmacy in California . He assumed his ... "Jim is a great fit for Provista," says Jody ...
Breaking Medicine Technology: